In Brief This Week: Bio-Rad; PacBio; Qiagen; SQI Diagnostics; Integrated DNA Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – In the latter half of 2013, Bio-Rad Laboratories accrued $35 million in costs associated with its initial efforts to resolve investigations into violations of federal anti-bribery laws, the company said in its Form 10-K this week. The company had previously said that in 2010 it disclosed to the US Department of Justice and the US Securities and Exchange Commission that conduct by certain of its overseas operations may have violated the anti-bribery provisions of the US Foreign Corrupt Practices Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.